Fig. 3
From: Targetable vulnerabilities in T- and NK-cell lymphomas identified through preclinical models
Targeting MDMX and MDM2 with ALRN-6924 a Copy number variants and RNA expression levels of MDM2, MDMX, and TP53 across 21 T- and NK-cell lymphoma cell lines. b Protein levels of MDM2, MDMX and p53 by immunoblotting, corresponding to a. c TP53 mutation status, corresponding to a. d IC50 values of ALRN-6924 and RG-7112, corresponding to a. Bar graphs indicate mean values of at least two independent experiments performed in quadruplicates with error bars indicating standard error of the mean. Statistics: Unpaired two-sided t-test, *p < 0.05, **p < 0.01. e Tumor burden at all involved sites for each mouse. Tumor involvement is represented as % tumor weight per body weight for subcutaneous (s.c.) tumors, % spleen per body weight and % infiltration of hCD45/hCD2+ cells for bone marrow (BM) and peripheral blood (PB). Liver involvement is presented in grams, assessed by liver weight x % infiltration of hCD45/hCD2+ cells. Comparisons are by two-sided t-test with Welch correction. Error bars indicate standard error of the mean. f PET-CT scan showing axillary lymph node involvement with AITL at two sites (circled) prior to treatment with ALRN-6924 and complete remission after cycle 6
